Arch Biopartners (ARCH) AI Stock Analysis

• Market Cap: C$109.08M
• Dividend Yield: N/A
• Average Volume (3M): 24.07K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.97
• Revenue Growth: N/A
• EPS Growth: -78.59%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 66,106,370
• 10 Day Avg. Volume: 24,126
• 30 Day Avg. Volume: 24,070
• PEG Ratio: -2.33
• Price to Book (P/B): -26.13
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -41.59
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 26 Underperform
• Price Target: ―

Arch Biopartners is currently facing significant financial distress with no revenue generation, large operational losses, and negative equity. These factors heavily weigh down its overall score. Technical indicators are mixed, showing some bearish signals but not overly negative. Valuation is also a concern, with a negative P/E ratio and no dividend yield. Strategic improvements are crucial for future stability and growth.

Arch Biopartners Business Overview & Revenue Model

Company Description

Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, a drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The company is based in Toronto, Canada.

How the Company Makes Money

Arch Biopartners primarily generates revenue through the development and commercialization of its drug candidates. The company invests in the research and development of its proprietary technologies, aiming to bring them to market either independently or through strategic partnerships with larger pharmaceutical companies. Revenue streams include potential licensing agreements, milestone payments, and royalties from successful commercialization of its drug candidates. Additionally, Arch Biopartners may receive government grants or research funding to support its development efforts, particularly for projects addressing unmet medical needs.

Arch Biopartners Financial Statement Overview

Summary

Arch Biopartners exhibits severe financial challenges across all primary financial statements. The absence of revenue, large operational losses, negative equity, and reliance on financing indicate a precarious financial position. Strategic interventions are needed to stabilize and improve financial health.

Income Statement

Arch Biopartners is facing significant challenges in its income statement. The company has reported zero revenue in the latest year, indicating a complete halt in sales or service income. Historical data shows a declining trend in revenue with consistent losses, as evidenced by negative EBIT and net income margins. The lack of profitability and revenue growth are major concerns.

Balance Sheet

The balance sheet reflects a highly leveraged position with negative stockholders' equity, signaling financial instability. The debt-to-equity ratio cannot be calculated due to negative equity, which poses a significant risk. Total liabilities surpass total assets, indicating insolvency. There is a negative equity ratio, highlighting financial distress.

Cash Flow

Arch Biopartners has negative free cash flow, reflecting insufficient cash generation from operations to cover capital expenditures and operating needs. With no operating cash flow and continuous negative free cash flow, the company is reliant on external financing, as seen in positive financing cash flows.

Breakdown	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	2.12M	1.98M	964.68K	3.89M	67.89K
Gross Profit	0.00	-129.00K	-503.00K	-150.00K	-2.12M
EBITDA	-3.53M	-336.00K	-101.00K	-77.02K	-4.45M
Net Income	-3.92M	-3.33M	-1.41M	-1.17M	-4.63M
Balance Sheet
Total Assets	935.62K	1.17M	621.64K	2.67M	741.30K
Cash, Cash Equivalents and Short-Term Investments	2.97K	831.27K	506.35K	448.24K	653.68K
Total Debt	2.77M	5.02M	4.41M	5.16M	3.39M
Total Liabilities	5.28M	6.68M	5.09M	6.55M	4.61M
Stockholders Equity	-4.35M	-5.51M	-4.47M	-3.88M	-3.87M
Cash Flow
Free Cash Flow	-2.33M	-234.08K	-1.08M	-2.98M	-1.90M
Operating Cash Flow	-2.33M	-234.07K	-1.08M	-2.98M	-1.90M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	1.50M	559.00K	-421.37K	2.78M	2.16M

Arch Biopartners Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.64
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ARCH, the sentiment is Negative. The current price of 1.64 is below the 20-day moving average (MA) of 1.74, below the 50-day MA of 1.77, and below the 200-day MA of 1.84, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 36.97 is Neutral, neither overbought nor oversold. The STOCH value of 29.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ARCH.

Arch Biopartners Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.61B	0.11	-63.03%	2.07%	16.35%	0.29%
ARCH	26 Underperform	C$109.08M	―	90.17%	―	―	-78.59%
ONCY	―	$107.93M	―	-211.24%	―	―	―
MSCLF	―	$73.38M	―	-64.18%	―	―	―
MDNA	53 Neutral	C$57.02M	―	-97.22%	―	―	-67.03%
FENC	―	$241.81M	―		―	―	―
EPRX	45 Neutral	C$274.91M	―	-108.05%	―	―	―